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The p53 tumor suppressor protein regulates
many genes that can determine different cellular
outcomes such as growth arrest or cell death.
Promoter-selective transactivation by p53, al-
though critical for the different cellular out-
comes, is not well understood. We report here
that the human cellular apoptosis susceptibility
protein (hCAS/CSE1L) associates with a subset
of p53 target promoters, including PIG3, in
a p53-autonomous manner. Downregulation of
hCAS/CSE1L decreases transcription from
those p53 target promoters to which it preferen-
tially binds and reduces apoptosis. In addition,
hCAS/CSE1L silencing leads to increasedmeth-
ylation of histone H3 lysine 27 within the PIG3
gene. hCAS/CSE1L was previously shown to
function as a nucleo-cytoplasmic transport fac-
tor, as does its closely related yeast homologue
Cse1, which can also associate with chromatin
and serve as a barrier protein that prevents
spreading of heterochromatin. Thus, human
CAS/CSE1L can bind select genes with signifi-
cant functional consequences for p53-mediated
transcription and determine cellular outcome.
INTRODUCTION
Regulation by p53 of a wide variety of its target genes con-
tributes to the typeandsensitivity of cellular response todif-
ferent forms of stress (Bates and Vousden, 1999; Laptenko
and Prives, 2006; Levine, 1997; Prives and Hall, 1999; Vo-
gelstein et al., 2000). It is likely that unique sets of p53-reg-
ulated genes are responsible for different outcomes, such
as cell cycle arrest, senescence, or apoptosis, in response
to distinct stimuli. Several models have been proposed to
explain p53 selection of its target promoters.638 Cell 130, 638–650, August 24, 2007 ª2007 Elsevier Inc.Activation of distinct promoters and ensuing apoptosis
are at least partially determined by the overall level of p53
protein (Chen et al., 1996; Ludwig et al., 1996; Ronen et al.,
1996), posttranslational modifications of p53 including
phosphorylation (e.g., Ser46), acetylation and methylation
(Appella and Anderson, 2001; Bode and Dong, 2004;
Brooks and Gu, 2003; Chuikov et al., 2004; Huang et al.,
2006), and interaction with proteins such as ASPP1/2
(Samuels-Lev et al., 2001), JMY (Shikama et al., 1999),
Mdm2 (Minsky and Oren, 2004; Ohkubo et al., 2006), or
other p53 family members (Flores et al., 2002).While these
may partially explain the molecular mechanism of p53
promoter discrimination, this phenomenon is still incom-
pletely understood.
We used a multifaceted experimental approach that
couples chromatin immunoprecipitation (ChIP) with size-
fractionation by sucrose gradient ultracentrifugation and
mass spectrometry to isolate functionally distinct
promoter-bound p53 assemblies in vivo. This led to the
identification of hCAS/CSE1L as a component of some
chromatin-bound p53 transcriptional complexes. The
cellular apoptosis susceptibility gene (hCAS) is the human
homolog of the essential yeast chromosome segregation
gene 1 (Cse1; Brinkmann et al., 1995; Xiao et al., 1993).
hCAS/CSE1Lwasoriginally identified in a screen for genes
that render breast cancer cells resistant to apoptosis after
certain treatments (Brinkmann et al., 1995; Xiao et al.,
1993). Expression of mutant yeast Cse1 was shown to
cause defects in chromosome segregation and B-type
cyclin degradation (Irniger et al., 1995; Xiao et al., 1993).
hCAS/CSE1L was then shown to function as a specific
nuclear transport factor to regulate Importin-a (Kap60p)
transfer from the nucleus to the cytoplasm in human cells
(Kutay et al., 1997). A screen in yeast for boundary proteins
that prevent the spread of heterochromatin and silencing
of the HML locus identified several components of the
nuclear pore complex and transport factors, including
Cse1 (Ishii et al., 2002). Indeed, a number of nuclear-cyto-
plasmic transport proteins are associated with discrete
sets of transcribed genes which may be repositioned to
the nuclear pore (Casolari et al., 2004). hCAS/CSE1L is
highly expressed in proliferating human cells, suggesting
that it canplaymultiple roles in addition to apoptosis (Brink-
mannetal., 1995).Our results implicate a functional interac-
tion between hCAS/CSE1L and the p53 tumor suppressor
protein leading to critical changes in the p53 response.
RESULTS
Fractionation of p53-Containing Complexes
Associated with Chromatin
To separate and isolate different promoter-bound p53
protein assemblies, cell extracts from formaldehyde
crosslinked or untreated H1299 cells expressing adeno-
virally transduced p53 (Ad-p53; Figure 1A) or tetracy-
cline-regulated p53 that is expressed at physiological
levels (Chen et al., 1996; Menendez et al., 2006;
Figure 1B) were subjected to sucrose gradient ultracentri-
fugation. In untreated cell lysates (), p53 was detected
primarily in the more slowly sedimenting fractions, while
p53 from formaldehyde crosslinked cells (+) sedimented
broadly through the gradient, indicating its participation
in multiple crosslinkable complexes in vivo (Figure 1A).
The distribution of actin indicated that p53 sedimention
was not due to nonspecific crosslinking or protein aggre-
gation (Figure 1B). ChIP analysis showed p53 association
with p21 and HDM2 promoters in both intermediately and
rapidly sedimenting gradient fractions, while p53 at PIG3
and p53AIP1 promoters was exclusively in the most
rapidly sedimenting fractions (Figure 1C). PCR analysis
of DNA from intermediate and rapidly sedimenting frac-
tions (#11 and #17) performed with the above and two ad-
ditional p53 targets, BAX and PUMA, again revealed two
general size classes of promoters bound by p53
(Figure 1D). Thus, distinct promoter-bound p53 multipro-
tein complexes can be separated by size-fractionation.
Identification of hCAS/CSE1L within
p53-Containing Crosslinked Complexes
Sucrose gradient fractionated fractions #7, 11, and 17
from crosslinked cells were immunoprecipitated using
anti-p53 monoclonal antibodies followed by SDS-PAGE
and silver staining (Figure S1). Several polypeptides
were identified by mass spectrometry that were unique
to these fractions. Six matching peptides from the cellular
apoptosis susceptibility protein (hCAS/CSE1L) were pres-
ent in one minor unique band excised from the heavier
p53-associated fraction #17 (Figures 1E and S1) that
was not in the intermediate (#11) or slower (#7) sediment-
ing fractions. The yeast homolog of hCAS/CSE1L was
shown to have a direct role in regulation of gene expres-
sion, thus prompting us to examine the possible relation-
ship of hCAS/CSE1L to p53.
Coassociation of p53 and hCAS/CSE1L in Human
Cell Lines
hCAS/CSE1L protein could be detected in immunoprecip-
itates of Ad-p53 from extracts of crosslinked H1299 cells,
and a weak signal above background was even detectedin uncrosslinked cell lysates (Figure 2A). The specificities
of anti-hCAS/CSE1L antibodies and siRNAs used in our
experiments are shown in Figures S2, S3, and S5. Impor-
tantly, when crosslinked sonicated cell extracts were sub-
jected to sucrose gradient sedimentation as in Figure 1,
hCAS/CSE1L coimmunoprecipitated with p53 in the rap-
idly sedimenting fraction (#17), but not in the intermediate
sedimenting fraction (#11; Figure 2B). In fact, the sucrose
gradient sedimentation profile of hCAS/CSE1Lwas similar
to that of p53, further indicating that the two proteins were
present together in a subset of their respective crosslink-
able complexes (Figure S2B).
To investigate the interaction between endogenously
expressed p53 and hCAS/CSE1L, MCF-7 cells harboring
wild-type p53 were either left untreated (control) or treated
with adriamycin and then crosslinked with formaldehyde.
Endogenous hCAS/CSE1Lwas detectable within anti-p53
immunoprecipitates, and this was markedly augmented
when p53 levels were increased following DNA damage
(Figure 2C). Reciprocally, p53 could be detected in immu-
noprecipitates of hCAS/CSE1L in lysates of either H1299
cells expressing ectopic p53 (Figure 2D) or MCF-7 cells
expressing endogenous p53 after adriamycin treatment
(Figure 2E). Since hCAS/CSE1L could not be detectably
coimmunoprecipitated with ectopically expressed HA-
tagged E2F1 from crosslinked H1299 cell extracts, it
does not associate with all mammalian transcription
factors (Figure 2F).
Levels of hCAS/CSE1L Affect Induction of Select
p53 Target Genes and Apoptosis
The effect of hCAS/CSE1L downregulation on p53 tran-
scriptional activity was examined by transfecting MCF-7
cells with either hCAS/CSE1L RNAi or control RNAi for
48 hr after which cells were either untreated or treated
with camptothecin (CPT) for 16 hr. Although hCAS/
CSE1L protein levels were significantly reduced by
hCAS/CSE1L RNAi, p53 protein levels were unaffected
(Figure 3A). While reducing hCAS/CSE1L had virtually no
effect on protein levels of HDM2 and only a modest effect
on the accumulation of p21 protein, there was a significant
inhibition of PIG3 protein accumulation following DNA
damage. Similar results were obtained with H1299 cells
infected with adenoviruses expressing either LacZ or
p53 (Figure S4A). A concentration range of two different
hCAS/CSE1L RNAi sequences (#2 and #3) caused pro-
portionate levels of reduction of both hCAS/CSE1L and
PIG3, again with negligible effects on p21 or p53
(Figure S5).
In line with these results PIG3 mRNA induction by p53
was significantly suppressed after hCAS/CSE1L downre-
gulation with little effect on p21 mRNA induction
(Figure 3B). Additionally, p53 induction of p53AIP1 and
p53R2 mRNAs was also significantly reduced by hCAS/
CSE1L silencing, whereas 14-3-3s and PUMA were not
affected. Similar results were obtained using H1299 cells
expressing ectopic p53 (Figure S4B). PIG3, PUMA, and
p53AIP1 are proapoptotic proteins, while p21, p53R2,Cell 130, 638–650, August 24, 2007 ª2007 Elsevier Inc. 639
Figure 1. Identification of hCAS /CSE1L in High-Molecular-Weight Crosslinked Complexes Containing p53
(A) Sucrose gradient centrifugation fractionation of p53 complexes. H1299 cells were infected with a recombinant adenovirus expressing wild-type
p53 (30 MOI) and then were treated or not with formaldehyde as indicated (Crosslink + or ) prior to extraction and sonication as described in
Experimental Procedures. Extracts (2.5 mg protein) were then subjected to ultracentrifugation through a 10%–40% sucrose gradient. Collected
gradient fractions were reverse crosslinked and then 20 ml of each fraction were subjected to immunoblotting with anti-p53 antibody (DO1).
(B) Fractionation of p53 complexes after DNA damage in H1299 cells expressing tetracycline-regulated p53. p53 in H24-14 cells clonally derived from
H1299 cell line was induced by removal of tetracycline for 24 hr, and then cells were first treatedwith adriamycin (3 mM) for 16 hr and then treated or not
with formaldehyde prior to extraction and sonication. Sucrose gradient centrifugation and immunoblotting with anti-p53 (DO1) and anti-actin
antibodies were performed as in (A).
(C) ChIP profiling of size-fractioned p53 chromatin complexes. Crosslinked cell extracts were subjected to sucrose gradient sedimentation and frac-
tionation as in (A). Upper panel: Anti-p53 immunoblot with 20 ml of each gradient fraction. Lower panels: ChIP analysis; each sucrose fraction (500 ml)
was immunoprecipitated with anti-p53 antibodies (DO1/ 1801), then input (first lanes) and immunoprecipitated DNA from each fraction were purified
and subjected to PCR to detect p53 associated with p53 target gene promoters as described in Experimental Procedures. PIG3 318 refers to
canonical p53 binding site at 328/309 in the PIG3 gene (see Figure 5A). DNA size markers are in second lanes.
(D) ChIP profiling of target genes associated with intermediate or high-molecular-weight p53 complexes. ChIP analysis was performed using fractions
(Fr) #11 and #17 of a sucrose gradient as in (A) from cells infected with recombinant adenoviruses expressing either LacZ or p53 using primers span-
ning p53 binding sites within the indicated p53 target genes. Representative images are shown in left panel. PCR products were quantified using
Kodak gel imaging software, and quantification representing the average of three independent experiments is shown in right panel. Input lanes
were from the p53-expressing samples.
(E) hCAS/CSE1L sequence. Isolation and identification of hCAS/CSE1L polypeptide from p53-associated rapidly sedimenting crosslinked protein
complexes are described in Experimental Procedures and Figure S1. Sequence of hCAS/CSE1L is shown with underlined matched peptide
sequences identified by mass spectrometry.and 14-3-3s are not. Therefore, responses to hCAS/
CSE1L downregulation were neither exclusive to proa-
poptotic genes nor did all proapoptotic targets require
hCAS/CSE1L for full expression. Nonetheless, in conjunc-
tion with our observations that hCAS/CSE1L was found
associated with p53 only in the most rapidly sedimenting
complexes, these data indicate that hCAS/CSE1L plays640 Cell 130, 638–650, August 24, 2007 ª2007 Elsevier Inc.a role in regulating expression of a specific subset of
p53 target genes.
Since at least two proapoptotic target genes were re-
duced by hCAS/CSE1L downregulation, we examined
whether reduced levels of hCAS/CSE1L affect DNA
damage-induced apoptosis. When MCF-7 cells were
transfected with control RNAi (Luciferase RNAi) or two
Figure 2. Interaction of hCAS/CSE1L with p53 In Vivo
(A) hCAS/CSE1L associates with p53 in crosslinked H1299 cells. Cells were infected with p53 or LacZ adenoviruses and then treated with or without
formaldehyde (Crosslink: + or) prior to extraction and sonication. Extracts were immunoprecipitated with anti-p53 DO1/1801 Protein G Sepharose
beads followed by SDS-PAGE and immunoblotting (IB) with anti-hCAS/CSE1L (upper panel) and anti-p53 DO1 (lower panel). LC refers to immuno-
globulin light chain.
(B) hCAS/CSE1L associates with p53 in rapidly sedimenting complexes. Fractions #11 and #17 from sucrose gradient shown in Figure 1A were
immunoprecipitated with anti-p53 DO1/1801 Protein G Sepharose beads followed by SDS-PAGE and immunoblotting with anti-hCAS/CSE1L (upper
panel) and anti-p53 DO1 (lower panel) antibodies.
(C) hCAS/CSE1L associates with endogenously expressed p53. MCF-7 cells were treated or not with adriamycin (2 mM) for 16 hr and then immuno-
precipitated with anti-p53 DO1/1801 Protein G Sepharose beads prior to SDS-PAGE and immunoblotting with anti-hCAS/CSE1L (upper panel) and
anti-p53 DO1 (lower panel) antibodies. Input represents 5% of total lysate.
(D and E) p53 is present in anti-hCAS/CSE1L immunoprecipitates. H1299 cells infected with p53 or LacZ adenoviruses (D) or MCF-7 cells treated or
not with adriamycin (2 mM) for 16 hr (E) were then treatedwith formaldehyde prior to extraction and sonication. Extracts were then immunoprecipitated
with anti-hCAS/CSE1L (hCAS #689/#692) or control IgG coupled to Protein G Sepharose beads followed by SDS-PAGE and immunoblotting (IB) with
anti-hCAS/CSE1L (upper panel) and anti-p53 DO1 (lower panel). Inputs represent 5% of total lysate.
(F) hCAS/CSE1L does not associate with E2F1. H1299 cells were transfected with a construct expressing HA-E2F1 for 24 hr and then treated with
formaldehyde prior to extraction and sonication. Extracts were then immunoprecipitated with anti-HA Protein G Sepharose beads followed by SDS-
PAGE and immunoblotting (IB) with anti-hCAS/CSE1L (upper panel) and anti-HA antibody (lower panel).hCAS/CSE1L siRNAs (#2 or #3; see Figure S5) and then
treated or not with UVC radiation, the ensuing apoptosis
was less than half of that seen with the control siRNA
(Figure 3C). Confirming a previous report (Latonen and
Laiho, 2005), UVC-induced cell death was greatly reduced
when p53 was silenced (Figure S6). Thus, extending ear-
lier findings for a role for hCAS/CSE1L in some types of
apoptosis (Brinkmann et al., 1995, 1996), hCAS/CSE1L
facilitates cell death caused by a form of stress that is
linked to the regulation and function of p53.
hCAS/CSE1L Binds to Select p53 Target
Genes In Vivo
We determined whether hCAS/CSE1L itself associates
with p53 target promoters. The primary amino acid
sequence of hCAS/CSE1L suggests two potential DNA-interacting domains, one a short basic region within
residues 372–385 that was predicted to both contain a
nuclear localization signal as well as a possible DNA-bind-
ing module, and the second a potential zinc finger motif
(His-Xaa2-His-Xaa6-Cys-Xaa6-Cys) within amino acids
613–630 (Figure 4A; Brinkmann et al., 1995). The basic
region of hCAS/CSE1L is highly conserved from yeast to
humans, whereas the putative zinc finger motif region is
less well conserved (Figure 4B). Vectors expressing either
FLAG-tagged wild-type hCAS/CSE1L or mutant versions
deleting either the basic region (D372—385/hCAS) or
zinc finger motif (D613–630/hCAS) were introduced into
U2OS cells (Figure 4A). Protein levels of either hCAS/
CSE1L deletion mutant were consistently lower than
wild-type hCAS/CSE1L (Figure 4C, upper panel). When
anti-FLAG antibody (M2) was used to measureCell 130, 638–650, August 24, 2007 ª2007 Elsevier Inc. 641
Figure 3. hCAS/CSE1L Regulates Induction of Select p53 Target Genes and Apoptosis
(A) Selective effects of hCAS/CSE1L downregulation on p53 target protein levels in MCF-7 cells. Cultures were transfected with luciferase siRNA
(control RNAi) or hCAS/CSE1L siRNA (hCAS RNAi #1) for 48 hr, and then cells were either not treated (control) or treated with CPT for 16 hr. Cell
extracts (20 mg) were resolved by SDS-PAGE and subjected to immunoblotting with antibodies against hCAS/CSE1L (hCAS 30F12), p53 (DO1),
HDM2, p21, PIG3, or Actin as indicated.
(B) hCAS/CSE1L downregulation reduces expression of select p53 target genes. MCF-7 cells were transfectedwith luciferase siRNA (control RNAi) or
hCAS/CSE1L siRNA (hCAS RNAi #1) as in (A). Total RNA was subjected to real-time RT-PCR analysis. Expression levels of actin, hCAS/CSE1L, p53,
p21, 14-3-3s, PUMA, p53R2, PIG3, and p53AIP1 RNAs were determined by the comparative threshold cycle method.
(C) hCAS/CSE1L downregulation protects MCF-7 cells from apoptosis. MCF-7 cells were transfected with luciferase siRNA (control RNAi) or two
different hCAS/CSE1L siRNAs (hCAS RNAi #2) or (hCAS RNAi #3) for 48 hr, and then cells were either not treated (Untreated) or treated with UVC
radiation (UVC 20 J/m2) for 36 hr. Left Panel: Cells were collected, fixed in cold methanol, and subjected to FACS analysis. Upper right panel: Immu-
noblotting of hCAS/CSE1L in extracts of parallel cultures treated with control or hCAS/CSE1L siRNAs #2 and #3. Lower right graph: Percent of cells
with sub-G0/G1 DNA content after treatment with or without UVC with either control siRNA or hCAS/CSE1L siRNAs #2 or #3. The average of three
independent experiments is shown with error bars indicating standard deviation.642 Cell 130, 638–650, August 24, 2007 ª2007 Elsevier Inc.
Figure 4. hCAS/CSE1L Associates with
Select p53 Target Promoters In Vivo
(A) Sequence motifs of hCAS/CSE1L protein.
Upper diagram shows hCAS/CSE1L polypep-
tide with three sequence motifs. Amino acids
372–385 contain several basic residues
which could comprise DNA recognition or
nuclear localization motifs; amino acids
613–630 (His-Xaa2-His-Xaa6-Cys-Xaa6-Cys)
might form a zinc finger. Lower diagrams
show deletion mutants lacking either the
basic region (middle) or the potential zinc
finger (bottom).
(B) Amino acids 372–385 but not 613–630 are
well conserved in CAS/CSE1L. The alignments
of basic region and zinc finger motif includes
hCAS/CSE1L homologs from S. cerevisiae
(Yeast),D.melanogaster (Drome),M.musculus
(Mouse), and H. sapiens (Human). Conserved
residues are highlighted.
(C) hCAS/CSE1L association with the PIG3
promoter is reduced by deleting residues
372–385. U2OS cells were transfected with
empty vector, FLAG-tagged wild-type hCAS/
CSE1L (WT-hCAS), FLAG-tagged hCAS/
CSE1L lacking residues 372–385 or residues
613–630 (D372–385/hCAS and D613–630/
hCAS, respectively) for 24 hr. Upper two
panels: aliquots of crosslinked and sonicated
transfected cell extracts were used for immu-
noblotting with either anti-FLAG (M2) or anti-
actin antibodies. Lower two panels: A ChIP
assay using anti-FLAG (M2) antibody was per-
formed using same extracts of crosslinked
cells transfected with FLAG-tagged wild-type
or the two deletion mutants shown in (A) to
detect association of hCAS/CSE1L with the
PIG3 p53-binding-site (318) region (PIG3
BS). GAPDH is shown as a negative control.
(D and E) Autonomous association of hCAS/
CSE1L with select p53 target gene promoters.
H1299 cells infected with LacZ or p53 (p53WT)
adenoviruses for 24 hr (D) and MCF-7 cells
either not treated or treated with CPT (300
nM) for 24 hr (E) were treated with formalde-
hyde prior to extraction and sonication. A
ChIP assay was performed using anti-p53
(DO1/1801) or anti-hCAS/CSE1L antibodies
(hCAS #689/#692) using primers to amplify sequences spanning p53 binding sites within the indicated p53 target gene promoters as described
in Experimental Procedures.
(F) hCAS/CSE1L and p53 are simultaneously present within the PIG3 promoter.
H1299 cells infected with adenoviruses expressing ether LacZ or wild-type p53 for 24 hr were treated with formaldehyde prior to sonication and
extraction. Extracts were first subjected to immunoprecipitation with anti-p53 (DO1/1801) or control IgG (ChIP), and then eluates were subjected
to a subsequent immunoprecipitation with hCAS/CSE1L (hCAS #689/#692) antibodies or control IgG (ReChIP). In both cases DNA was recovered
and amplified by PCR as described in Experimental Procedures.association of ectopic wild-type hCAS/CSE1L with the
p53 binding site at 318 within the PIG3 promoter, there
was a strong signal over the vector control (Figure 4C,
lower panels). While binding by the putative zinc finger-
deleted version of hCAS/CSE1L was reduced (consistent
with its lower levels), deletion of the basic region of hCAS/
CSE1L virtually abrogated the association of ectopic
hCAS/CSE1L with the PIG3 promoter (Figure 4C). The
inability of the D372–385/hCAS mutant to associate withchromatin is not due to a nuclear localization defect
(Figure S7), suggesting that sequences within the basic
region play a role in the association of hCAS/CSE1L with
chromatin.
We then performed ChIP assays with either H1299 cells
infected with adenoviruses expressing p53 or MCF-7 cells
thatwere either untreatedor treatedwith camptothecin. Pre-
dictably, p53 was found associated with regions containing
its binding sites within several promoters in H1299 cellsCell 130, 638–650, August 24, 2007 ª2007 Elsevier Inc. 643
Figure 5. Differential Interactions of
hCAS/CSE1L and p53 with the PIG3 and
p21 Promoters
(A) ChIP scanning of p53 or hCAS/CSE1L at
different PIG3 promoter regions. H1299 cells
infected with a wild-type p53 adenovirus for
24 hr were treated with formaldehyde prior to
sonication and extraction. Extracts of p53-
expressing cells were subjected to a ChIP
assay with anti-p53 (DO1/1801) or hCAS/
CSE1L (hCAS #689/#692) antibodies using
real-time PCR using indicated primers shown
on the map (top).
(B) hCAS/CSE1L is not associated with p53
binding regions in the p21 promoter. H1299
cells were infected with adenoviruses express-
ing either LacZ or p53 (p53WT) for 24 hr and
were treated as described in (A). A ChIP assay
was performed using anti-p53 (DO1/1801),
anti-hCAS/CSE1L antibodies (hCAS #689/
#692), or without antibody (no Ab), then input
and immunoprecipitated DNA were purified
and subjected to real-time PCR to quantify as-
sociation with the PIG3 (318) p53 binding
site, the p21 50 (2272) or the p21 30 (1421)
p53 binding sites.expressing adenovirally transduced p53 but not LacZ
(Figure4D). InMCF-7cellsbasalp53binding toeachof these
promoters was increased after CPT treatment, undoubtedly
related to the increased levels of p53 caused by treatment
with this agent (Figure 4E). Endogenous hCAS/CSE1L was
associated with PIG3, p53AIP1, and p53R2 promoters in
both H1299 and MCF-7 cells, while the signal obtained
with p21 and PUMA promoters was either very weak or un-
detectable (Figures 4D and 4E). Thus, there was a striking
correlation between binding of hCAS/CSE1L uniquely to
those promoters of p53 target genes (PIG3, p53AIP1, and
p53R2) whose induction was reduced after hCAS/CSE1L
downregulation. Unexpectedly, hCAS/CSE1L was also as-
sociated with these promoters in the absence of p53 in
H1299 cells, showing that promoter binding by hCAS/
CSE1L is independent of p53 (Figure 4D).
To determine whether p53 and hCAS/CSE1L are
concurrently associated with the PIG3 promoter, we
performed a serial ChIP experiment (Figure 4F). As we
were able to obtain robust and specific signals with both
the ChIP and Re-ChIP fractions, p53 and hCAS/CSE1L
are present at the PIG3 promoter at the same time within
a crosslinkable complex. Nonetheless, despite their
simultaneous presence, neither hCAS/CSE1L (Figure 4D)
or p53 (Figure 6A) are required for the interaction of the
other protein at the PIG3 promoter.
We examined in more detail hCAS/CSE1L and p53 as-
sociation with the PIG3 promoter using real-time PCR
(Figure 5A; see diagram indicating primer sets). Two
separate binding sites for p53 within the PIG3 promoter644 Cell 130, 638–650, August 24, 2007 ª2007 Elsevier Inc.have been identified. The first conforms to the canonical
p53 binding sequence and is located at 328/309 (Pol-
yak et al., 1997), and the second is within a microsatellite
region at +442/+516 (Contente et al., 2002). Peak binding
signals for p53 were detected at both p53 binding sites,
with significant signal also detected both between these
sites, i.e., in the vicinity of nucleotide +223 and within a
region approximately 500 bp upstream of the first binding
site (833). Little or no binding by p53 was detected
approximately 1.7 kb upstream from the canonical p53
binding site (1778). hCAS/CSE1L binding to the PIG3
promoter substantially differed from p53 in that it strongly
associated both with the 318 and 813 regions but
showed little or no association with regions within the
transcribed sequence at +223 or the microsatellite zone
(+509). Like p53, the signal at 1778 seen with hCAS/
CSE1L was negligible.
The p21 promoter also has two p53 binding sites at
2.1 and 1.3 kb, the 50 and 30 sites, respectively
(Macleod et al., 1995). hCAS/CSE1L did not associate
with either 50 or 30 p53 binding sites in the p21 promoter
(Figure 5B). Furthermore, ChIP analysis showed that
hCAS/CSE1L did not associate with several regions within
the PUMA locus in addition to its p53-binding-site region
(Figure S8A).
hCAS/CSE1L and p53 Coregulate Methylation
of Lysine 27 on Histone H3
Chromatin domains that are involved in establishment of
heterochromatin boundaries and epigenetic gene
regulation are defined by distinct sets of posttranslation-
ally modified histones. Modification of histone H3 by acet-
ylation at lysine 9 (K9) as well as methylation at lysine 4
(K4) is often suppressed in silenced heterochromatin
and enriched in active euchromatin (Ehrenhofer-Murray,
2004; Kouzarides, 2002; Lachner et al., 2003). In contrast,
histone H3 methylation at K9 (K9M-H3) and K27 (K27M-
H3) is enriched in regions of inactive heterochromatin
(Ehrenhofer-Murray, 2004; Kouzarides, 2002; Lachner
et al., 2003; Martin and Zhang, 2005; Sims et al., 2003).
Using H1299 cells expressing ectopic p53, we tested
the impact of downregulation of hCAS/CSE1L by siRNA
on histone H3 modifications within the PIG3 promoter at
the 318 site that is associated with both p53 and
hCAS/CSE1L (Figure 6A). ChIP analysis with specific anti-
bodies against p53, hCAS/CSE1L, or with histone H3
methylation-specific antibodies (tri-K4M-H3, di-K9M-H3,
and tri-K27M-H3) was performed. We confirmed that
both hCAS/CSE1L and p53 binding to the PIG3 318 re-
gion are independent of one another (Figure 6A, top left
panels). Little or no impact of reducing hCAS/CSE1L
levels on either trimethylation of lysine 4 (tri-K4M-H3) or
dimethylation of lysine 9 (di-K9M-H3) was detected
(Figure 6A, bottom left panels), while lysine 27 methylation
(tri-K27M-H3), a repressive modification for gene tran-
scription, was increased significantly at the region
spanning the canonical p53 binding site on the PIG3 pro-
moter when hCAS/CSE1L was downregulated (Figure 6A,
bottom right panel).
We then examined: (1) a region relatively far upstream
(2149), (2) the previously examined p53-binding-site
region (318), (3) the second region within the coding se-
quence (+223) where we had detected a ChIP signal with
p53 but not with hCAS/CSE1, and (4) a still further region
within Intron 2 (+2483) downstream of the transcription
start site (Figure 6B). While there was a relatively small im-
pact of hCAS/CSE1L downregulation on K27 trimethyla-
tion at the far upstream (2149) region, and there was
again somewhat less K27 trimethylation in the vicinity
of 318, remarkably, at +223 there was dramatically
less K27 methylation in the presence of p53 when there
were normal levels of hCAS/CSE1L, and this was substan-
tially reversed when hCAS/CSE1L was downregulated. In
fact, this was also seen at the far downstream (+2483) site.
Thus, p53 expression leads to reduced K27 methylation
within the transcribed region of the PIG3 gene, and this
requires hCAS/CSE1L, even though hCAS/CSE1L does
not itself interact with this region. Dimethylation of histone
H3 K9 at both the 318 and +223 sites was not signifi-
cantly affected by either downregulation of hCAS/CSE1L
or the presence of p53 (data not shown). These data impli-
cate hCAS/CSE1L as having a long-range effect on chro-
matin within a p53-regulated locus.
Trimethylation of histone H3 K27 at p53 binding sites
within the p53R2 and p53AIP1 promoters to which
hCAS/CSE1L binds (Figure 6C, left and middle panels, re-
spectively) as well as the same four regions within the
PUMA promoter where we failed to detect hCAS/CSE1Lassociation (Figure S8) was also examined. With p53R2
we obtained essentially similar results as seen with PIG3
at 318—namely increased signal when hCAS/CSE1L
was decreased and decreased signal when p53 was ex-
pressed which was partially restored by downregulation
of hCAS/CSE1L. The results were less pronounced with
the p53AIP1 promoter, although the tendency was the
same. Note that the extent of K27 methylation at both
p53AIP1 and p53R2 genes was markedly greater than
seen at the PIG3 gene. By contrast there was no impact
on a region within either the non-p53-regulated GAPDH
promoter at +2182 (Figure 6C, right panel) or several re-
gions within the PUMA promoter, including near and far
downstream regions (Figure S8B). In fact, there was very
little K27 methylation at the downstream regions at the
PUMA locus with or without p53.
Importantly, the impact of hCAS/CSE1L silencing on
histone H3 tri-K27 methylation at sites within the PIG3 or
p53AIP1 promoters in untreated or daunorubicin-treated
U2OS cells that harbor endogenous p53 revealed a similar
trend (Figure S9). It is intriguing that within those genes to
which hCAS/CSE1L binds we saw increased trimethyla-
tion of histone H3 K27 (albeit rather modest) without ex-
pression of p53. This effect likely requires an interaction
of hCAS/CSE1L with the promoter because it was not
seen within either GAPDH or PUMA genes.
Taken together, our data are consistent with the model
shown in Figure 7 that hCAS/CSE1L coregulates select
genes with p53 and the two proteins function together to
facilitate the formation of active chromatin at select tar-
gets in human cells.
DISCUSSION
Our modified version of the ChIP protocol revealed that
hCAS/CSE1L is uniquely present in high-molecular-
weight protein assemblies that interact with a subset of
p53 target gene promoters in vivo. There are several
different proteins exclusively present in intermediate and
rapidly sedimenting sucrose gradient fractions
(Figure S1; data not shown), and so this approach should
be useful for identification of other components of chro-
matin-associated complexes. Formaldehyde is a high-
resolution (2 A˚) crosslinking agent. Although we cannot
conclude that hCAS/CSE1L and p53 interact directly,
they are likely to be associated in a functional complex
that regulates gene expression. The approach described
herein may be further exploited to demonstrate relation-
ships between proteins that would be missed by more
conventional immunoaffinity proteomic methods.
Deletionof a short basic regionbetweenaminoacids372
and 385 in hCAS/CSE1L abrogated its interaction with the
PIG3 promoter in vivo (Figure 4C). To date, however, we
have not been able to obtain evidence for significant bind-
ing of recombinant hCAS/CSE1L protein to naked DNA
sequences spanning the regions of the PIG3 promoter
that provided strong ChIP signals with anti-hCAS/CSE1L
antibodies (unpublished data). Structures of yeast Cse1Cell 130, 638–650, August 24, 2007 ª2007 Elsevier Inc. 645
Figure 6. hCAS/CSE1L Levels Affect Histone H3 Lysine 27 Methylation
(A) hCAS/CSE1L downregulation selectively affects histone H3 lysine methylation at the PIG3 p53 binding site. H1299 cells were transfected with
control RNAi (Luciferase RNAi) or hCAS/CSE1L RNAi (hCAS RNAi #2) for 48 hr, and then cells were infected with adenoviruses expressing LacZ
or wild-type p53 for 24 hr. ChIP assays were performed to examine association of p53, hCAS/CSE1L, or histone H3 modifications within the region
of the PIG3 p53 binding site (318) using antibodies directed against p53 (DO1/1801), hCAS/CSE1L (hCAS#689/#692), tri-K4M-H3, di-K9M-H3, and
tri-K27M-H3.
(B) Long-range effects of hCAS/CSE1L on histone H3 lysine K27 methylation. H1299 cells were treated as described in (A). ChIP assays were
performed using real-time PCR to detect tri-K27M-H3 methylation status in the vicinity of the following regions: upstream p53 and hCAS/CSE1L646 Cell 130, 638–650, August 24, 2007 ª2007 Elsevier Inc.
Figure 7. Model of hCAS/CSE1L and p53
Coregulation of Select p53 Target Genes
p53 bound to its consensus sequence (red bar)
recruits general transcription factors, mediator
complex, and histone acetylases (HATs) to
facilitate initiation of transcription by RNA poly-
merase II (indicated by red arrow). hCAS/
CSE1L and p53 are present in a larger cross-
linkable complex that can inhibit repressive
lysine 27 (K27) methylation on histone H3.
Methylation of another repressive lysine (K9)
on histone H3 is reduced when p53 is present
but is not affected by hCAS/CSE1L. Inhibition
of HMTase is indicated as a possible mecha-
nism. Alternate scenarios exist, such as stimu-
lation of K27 demethylase activity.have been solved with (Matsuura and Stewart, 2004) and
without (Cook et al., 2005) its cargo Importin-a/Kap60p
andRan-GTP. Cse1 contains 20 HEAT (huntingtin, elonga-
tion factor 3, A subunit of PP2A and TOR) repeats,
sequence features that are present in importins and expor-
tins (Conti et al., 2006). The hCAS/CSE1L region (amino
acids 372–385) that we identified as being important for
hCAS/CSE1L association with chromatin lies within a con-
served hinge sequence that interrupts HEAT repeat 8 and
bridges the RanGTP and Importin-a/Kap60p-interacting
regions of Cse1. Perhaps this region, which in yeast Cse1
undergoes a conformational changedependent on binding
to its cargo (Cook et al., 2005), provides a surface for inter-
action either with chromatin or chromatin-associated
proteins. Determining how hCAS/CSE1L associates with
chromatin will be challenging, and we hope to obtain
insight into this question in the future.
It is highly relevant that a number of yeast nuclear trans-
port factors, including Cse1, associate with discrete sets
of active genes and can regulate their activity and nuclear
organization in yeast (Casolari et al., 2004; Feuerbach
et al., 2002; Kosova et al., 2000; Strambio-de-Castillia
et al., 1999). Our results show that this can also occur in
mammalian cells. Interestingly, like hCAS/CSE1L, two
components of the nuclear pore complex (NPC), Nup98
and Importin-a2, can associate with the PIG3 but not the
p21 or PUMA promoters (Figure S10). This suggests the
intriguing possibility that some p53-responsive genes
may be in close association with the nuclear periphery
or NPC. The selective regulation of p53 transcriptional
activity by hCAS/CSE1L is likely achieved through associ-
ation with p53 target gene promoters rather than throughits function as a nuclear export factor because hCAS/
CSE1L downregulation had little or no impact on subcellu-
lar localization and accumulation of p53 after DNA dam-
age (Figure S3). It is likely that hCAS/CSE1L regulates
genes other than p53 targets, given that its interactions
with such targets are independent of p53. Future studies
should provide amore global view of the genes with which
hCAS/CSE1L associates and regulates.
Levels of hCAS/CSE1L affect trimethylation of histone
H3 K27 at the PIG3 promoter without significant impact
on H3 K9, another repressive modification. It is especially
intriguing that the requirement for hCAS/CSE1L is much
more pronounced when p53 is present and when PIG3
is being transcribed actively. Whether or not the specific
mechanistic details by which hCAS/CSE1L blocks hetero-
chromatinization in yeast and human cells are well
conserved remains to be determined. A set of proteins,
sometimes termed the EED-EZH2 complex, trimethylates
histone H3 lysine 27 leading to recruitment or facilitation of
the activity of a second group of proteins, the polycomb
repressive complex 1 (PRC1; Cao and Zhang, 2004).
Possibly hCAS/CSE1L itself (or a hCAS/CSE1L-contain-
ing complex) prevents either the recruitment or activity
of histone lysine 27 methylating enzymes. Alternately
hCAS/CSE1L may augment K27 demethylase activity.
These are important avenues for future studies.
Interestingly, a component of the histone H3 lysine 27
methylating complex, EZH2, like hCAS/CSE1L, is fre-
quently present at supraphysiological levels in prostate
cancers (Rhodes et al., 2003; Varambally et al., 2002),
possibly due to its regulation by the RB-E2F pathway. Per-
haps abnormally high levels of EZH2 result in formation ofnegative binding site (2149), the p53 binding site (318), upstream transcribed region (+223), and downstream transcribed region in Intron 2 (+2483).
The average of three experiments is shown with error bars indicating standard deviation. Shown above is a diagram of the PIG3 gene where head-to-
head arrows indicate location of primer sets used in ChIPs, and nucleotide numbers refer to the center of the amplified region. The shaded area
upstream of +1 refers to the potential hCAS/CSE1L binding region. p53 BS1 and p53 BS2 refer to p53 binding sites (p53 consensus BS and TGYCC15
repeat region, respectively) as shown in Figure 5A.
(C) hCAS/CSE1L downregulation affects histone H3 lysine K27 methylation within p53R2 and p53AIP1 promoters but not within the GAPDH gene.
H1299 cells were treated and prepared as described in (A). ChIP assays were performed in which tri-K27M-H3 was assessed at p53 binding sites
within the p53R2 (+2648) and p53AIP1 (+1968) promoters or at a site within the GAPDH gene (+2182) using real-time PCR.Cell 130, 638–650, August 24, 2007 ª2007 Elsevier Inc. 647
a nonfunctional EZH2 complex (Cao and Zhang, 2004).
Likewise, hCAS/CSE1L levels and activity may need to
be tightly regulated. Of note, while under the conditions
shown in Figure 3D hCAS/CSE1L RNAi reduces apoptosis
caused by UVC, hCAS/CSE1L depletion, either by higher
doses of RNAi or at longer times after RNAi treatment
(approximately 4 to 5 days), leads to subsequent cell
death in MCF-7 cells and HCT116 cells (data not shown).
This is consistent with observations that mutant yeast
Cse1 displays a conditional lethal phenotype, homozy-
gous hCAS/CSE1L knockout mice are embryonic lethal,
and antisense-mediated depletion of hCAS/CSE1L even-
tually results in cell death in HeLa cells (Ogryzko et al.,
1997). Given its multiple roles in nuclear transport, chro-
matin regulation, and cell death, it is likely that strict
control of hCAS/CSE1L expression is a requirement for
it to function effectively. Future studies will hopefully
lead to a fuller understanding of this interesting protein
and its relationship to p53.
EXPERIMENTAL PROCEDURES
Cell Culture, Drugs, and Plasmids
H1299, MCF-7, 293, IMR90, and HCT116 cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% FBS and antibiotics. H1299 cells expressing tetracycline-
regulated p53 (clone H24-14) as previously described (Baptiste
et al., 2002; Chen et al., 1996) were maintained in RPMI 1640 medium
(Invitrogen, Carlsbad, CA) containing 10% FBS, 250 mg/ml G418,
2.5 mg/ml puromycin, and 5 mg/ml tetracycline. To induce p53 in
H24-14 cells, cultures were plated in media lacking tetracycline,
G418, and puromycin and 24 hr later were washed twice in media lack-
ing tetracycline. Adriamicin and camptothecin (Oncogene Research
Products, San Diego, CA) were dissolved in DMSO. The coding
sequence of an N-terminally His-tagged human hCAS/CSE1L in the
pQE30 vector, kindly provided by Dr. Dirk Gorlich (Universitate Heidl-
berg, Heiderberg, Germany) was cloned into the NotI/BamH1 site of
a 3xFLAG-CMV-7.1 mammalian expression vector (Sigma, St. Louis,
MO) to generate 3xFLAG-hCAS/CSE1L. Constructs expressing dele-
tion mutant forms of hCAS/CSE1L (D372–385/hCAS/CSE1L and
D613–630/hCAS/CSE1L) were generated by oligonucleotide-directed
mutagenesis (Quickchange, Stratagene) using the 3xFLAG-hCAS/
CSE1L plasmid. A construct expressing HA-tagged E2F1 was de-
scribed previously (Urist et al., 2004).
Western Blot Analysis and Antibodies
For protein analysis cells were harvested and subjected to immuno-
blotting as previously described (Urist et al., 2004). The following pri-
mary antibodies were used to detect specific proteins. hCAS/
CSE1L: anti-hCAS 30F12 (Novocastra UK); p53: DO1 hybridoma su-
pernatant; p21: anti-p21 (Ab-1; Oncogene Research); actin: anti-actin
(Sigma); HDM2: anti-HDM2, IF2 (Oncogene Research); anti-PIG3
(polyclonal) and anti-FLAG M2 antibodies (Sigma).
Two hCAS/CSE1L polyclonal antibodies were also raised (Covance)
against peptides corresponding to sequences within the N-terminus
(KKTLDPDPAIRRPAEC; hCAS#692) or C terminus (CDDTIPDEEH
FIDIED; hCAS#689). Crude rabbit serum was subjected to hCAS/
CSE1L affinity purification (a detailed protocol is available on request).
Specificity of these antibodies is shown in Figure S2.
Gene Transfer and RNA Interference
Recombinant adenoviruses encoding wild-type human p53 (p53WT)
or b-galactosidase (LacZ) were propagated in 293 cells, and then viral648 Cell 130, 638–650, August 24, 2007 ª2007 Elsevier Inc.titers were determined by a limiting dilution bioassay also using 293
cells. Infection of cells were performed by adding viral solutions to
cell monolayers and incubating at 37C for 60 min with brief agitation
at the indicated multiplicity of infection (MOI). For RNAi experiments,
21 nucleotide siRNA duplexes with 30 dTdT overhangs corresponding
to hCAS/CSE1L mRNA (hCAS RNAi #1, AAGCCAACATAGTGCACT
TGA; hCAS RNAi#2, AACCCTGCTGCTGTTGTAAAT; hCAS RNAi#3,
AACGGGTCAAGAGGTTAAATA) were synthesized by QIAGEN Inc.
(Valencia, CA). The sequence for control RNAi corresponding to firefly
luciferase mRNA was described previously (Urist et al., 2004). MCF-7
cells or H1299 cells were plated at 30%–40% confluency and trans-
fected with the indicated siRNA oligonucleotide (50 nM) using Dharma-
fect 1 (Dharmacon, Lafayette, CO). After 24 hr the cells received a
second dose of siRNA after which they were either left untreated or
exposed to camptothecin (CPT; 300 nM) and infected with recombi-
nant adenoviruses prior to lysis. For transfection of plasmids, H1299
cells were plated at greater than 80% confluency and transfected
with up to 5 mg of DNA with Lipofectamine 2000 (Invitrogen, Carlsbad,
CA) at a DNA:lipid ratio of 1:1.2.
Chromatin Immunoprecipitation Assay
H1299 or MCF-7 cells (each two 10 cm plates) were washed once in
13 phosphate-buffered saline (PBS) and then treated with 1% formal-
dehyde in PBS at 37C for 10 min, followed by quenching with glycine
(final concentration 0.125 M) for 5 min. Cells were scraped on ice and
centrifuged at 1,500 rpm for 5 min at 4C. After washing once with
PBS, cell pellets were resuspended gently in 1 ml of cold lysis buffer
A (10 mM HEPES-KOH pH 7.5, 1 mM EDTA, 400 mM NaCl, 10% glyc-
erol, 0.5%NP-40, 0.5 mM phenylmethylsulfonyl fluoride, 1 mM benza-
midine, 3 mg/ml leupeptin, 0.1 mg/ml bacitracin, and 1 mg/ml a2-mac-
roglobulin) followed by centrifugation at 13,000 rpm for 5 min at 4C.
The resulting pellets were then resuspended in 1 ml cold lysis buffer
A and sonicated with a W-220 sonicator (Heat Systems-Ultrasonics,
Inc.). The chromatin solution was cleared by centrifugation at 13,000
rpm for 10 min at 4C, and the supernatant (400 mg) was precleared
for 2–4 hr with 80 ml of a 50% slurry of Protein A/G Sepharose beads
(Amersham Biosciences). The Protein A/G Sepharose beads used
for immunoprecipitation were preblocked overnight at 4C with
sheared salmon sperm DNA (0.3 mg/ml) and BSA (1 mg/ml) and then
incubated with either amixture of monoclonal anti-p53monoclonal an-
tibody supernatants (DO1 and 1801), anti-hCAS/CSE1L polyclonal an-
tibodies (hCAS#689/#692), or anti-methyl-specific histone H3 anti-
bodies from Abcam (Cambridge, UK) including trimethyl K4 Histone
H3 (ab8580), dimethyl K9 Histone H3 (ab7312), or trimethyl K27 His-
tone H3 (ab6002). We predetermined amounts of anti-p53 antibodies
necessary for p53 immunodepletion (>90%). Immunoprecipitations
with the indicated antibodies were performed overnight at 4C and im-
mune complexes were eluted from the beads by adding 75 ml elution
buffer (50 mM Tris-HCl pH 8.0, 1% SDS, 10 mM EDTA) and heating
at 65C for 10 min twice. Reverse crosslinking was performed by incu-
bation of eluates or input chromatin at 65C overnight. The DNA was
then purified using the QIAquick PCR purification kit (Qiagen, Inc.),
and PCR was performed using the Expand High Fidelity PCR system
(Roche Applied Science, Indianapolis, IN). Approximately 1% of the
input chromatin sample and 5% of the ChIP sample were used as
template in each case. Reaction mixtures were initially melted at
94C for 5 min followed by 27 cycles of 94C for 30 s, 56C for 1 min,
72C for 1 min, and a final extension of 37C for 7 min. Amplicons were
visualized with ethidium bromide in 2.5% agarose gels.
For the re-ChIP assay the procedure for preparing the sonicated
lysate was the same as above, and then lysates were divided into
two aliquots which were immunoprecipitated with p53 antibodies
DO1/1801 or control IgG, coupled to protein A/G beads. One immuno-
precipitate was treated as above to extract DNA (ChIP sample), while
the other was incubated with re-IP elution buffer (50 mM Tris-HCl
pH 8.0, 1% SDS, 1 mM EDTA, 1 mM DTT) at 37C for 30 min twice
and then diluted 1:10 in lysis buffer A followed by a second
immunoprecipitation with anti-hCAS/CSE1L (hCAS #689/#692) or IgG
antibodies (reChIP sample). The complex was eluted as described for
the ChIP assay above, DNA was then purified using the QIAquick PCR
purification kit, and PCRwas performed using the Expand High Fidelity
PCR system with the following conditions: mixtures were initially
melted at 94C for 5 min followed by 30 cycles of 94C for 30 s,
56C for 1 min, 72C for 1 min, and a final extension of 72C for 7
min for ChIP and 35 cycles for re-ChIP. Amplicons were visualized
with ethidium bromide in 2.5% agarose gels. Primer sequences used
for all ChIPs are described in the Supplemental Data.
Real-Time PCR
For mRNA analysis, total RNA was isolated by RNeasy Mini Kit
(QIAGEN Inc.) and was converted to cDNA using the Superscript III
First Strand Synthesis System (Invitrogen). For either mRNA or ChIP
experiments Real-time PCR was performed using TaqMan FAM-
MGB probe and 23 TaqMan Universal PCR Master mix (Applied
Biosystems, Foster City, CA) on an ABI Prism 7700 Sequence Detec-
tion system (Applied Biosystems) with b-glucuronidase (GUD) serving
as an endogenous normalization control. Sequence Detection soft-
ware was utilized for data analysis, and relative fold induction was
determined by the comparative threshold cycle method using stan-
dard curves generated by plotting the observed CT value against the
standard dilutions of positive control sample. In all experiments the
average of three independent reactions is shown with error bars indi-
cating standard deviation.
FACS Analysis
Cells were collected and pelleted at 1,500 rpm for 10 min and then re-
suspended in 300 ml of cold PBS followed by fixation with ice-cold
methanol. At least 24 hr after fixation, cells were rehydrated in PBS
for 30 min and then repelleted as above. Cells were then reconstituted
in 1 ml of PBS containing 60 mg/ml propidium iodide and 50 mg/ml
RNase A. Cell cycle profiles were obtained using a FACScalibur flow
cytometer (BD Biosciences, San Jose, CA) and CellQuest software
(BD Biosciences).
Sucrose Gradient Sedimentation and Mass Spectrometry
For sucrose gradient fractionation, either H1299 cells were infected
with the indicated adenoviruses (p53 or Lac Z) for 20 hr or p53 was
induced in the H24-14 derivative H1299 cell line by removal of tetracy-
cline (Baptiste et al., 2002). In either case cells were treated as for ChIP
assay including lysis in buffer A, centrifugation, solubilization of pellets
in buffer A, and sonication. For western blotting analysis and ChIP
analysis as in Figures 1A–1D, 500 ml (5 mg/ml protein) of the sonicated
extract was layered directly onto a gradient of 10%–40% (W/V)
sucrose in 35 ml of IP buffer. Standard protein markers (100 mg
each) of thyroglobulin (670 kDa), gamma-globulin (158 kDa), and
bovine serum albumin (67 kDa) were layered onto parallel gradients.
Ultracentrifugation was performed with a Beckman SW28 rotor at
24,000 rpm for 30 hr. Fractions were collected in volumes of 1.75 ml
and aliquots taken for either immunoblotting (20 ml) or ChIP analysis
(500 ml).
Supplemental Data
Supplemental Data include ten figures and Discussion and can be
found with this article online at http://www.cell.com/cgi/content/full/
130/4/638/DC1/.
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